Mercer Global Advisors Inc. ADV Takes $204,000 Position in Nektar Therapeutics (NKTR)

Mercer Global Advisors Inc. ADV purchased a new position in Nektar Therapeutics (NASDAQ:NKTR) in the first quarter, HoldingsChannel reports. The firm purchased 6,082 shares of the biopharmaceutical company’s stock, valued at approximately $204,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. Dimensional Fund Advisors LP boosted its stake in Nektar Therapeutics by 4.3% during the 3rd quarter. Dimensional Fund Advisors LP now owns 224,471 shares of the biopharmaceutical company’s stock worth $13,683,000 after acquiring an additional 9,196 shares during the last quarter. Renaissance Technologies LLC boosted its stake in Nektar Therapeutics by 138.7% during the 3rd quarter. Renaissance Technologies LLC now owns 68,848 shares of the biopharmaceutical company’s stock worth $4,197,000 after acquiring an additional 40,000 shares during the last quarter. Vanguard Group Inc boosted its stake in Nektar Therapeutics by 3.6% during the 3rd quarter. Vanguard Group Inc now owns 18,922,650 shares of the biopharmaceutical company’s stock worth $1,153,525,000 after acquiring an additional 660,907 shares during the last quarter. State of Alaska Department of Revenue boosted its stake in Nektar Therapeutics by 6.0% during the 4th quarter. State of Alaska Department of Revenue now owns 48,377 shares of the biopharmaceutical company’s stock worth $1,589,000 after acquiring an additional 2,731 shares during the last quarter. Finally, QUANTRES ASSET MANAGEMENT Ltd boosted its stake in Nektar Therapeutics by 35.7% during the 4th quarter. QUANTRES ASSET MANAGEMENT Ltd now owns 17,500 shares of the biopharmaceutical company’s stock worth $575,000 after acquiring an additional 4,600 shares during the last quarter. Institutional investors and hedge funds own 94.90% of the company’s stock.

Shares of NKTR stock opened at $33.90 on Thursday. The company has a debt-to-equity ratio of 0.21, a quick ratio of 14.83 and a current ratio of 14.94. The company has a market cap of $5.68 billion, a price-to-earnings ratio of 8.97 and a beta of 2.96. Nektar Therapeutics has a 52 week low of $29.22 and a 52 week high of $92.17.

Nektar Therapeutics (NASDAQ:NKTR) last announced its earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.68) EPS for the quarter, topping the consensus estimate of ($0.71) by $0.03. The firm had revenue of $28.22 million for the quarter, compared to the consensus estimate of $25.45 million. Nektar Therapeutics had a net margin of 55.65% and a return on equity of 37.63%. During the same period last year, the company posted ($0.60) EPS. On average, analysts forecast that Nektar Therapeutics will post -3.05 EPS for the current year.

In other Nektar Therapeutics news, CEO Howard W. Robin sold 108,882 shares of the firm’s stock in a transaction that occurred on Thursday, February 21st. The shares were sold at an average price of $42.19, for a total transaction of $4,593,731.58. Following the sale, the chief executive officer now directly owns 350,924 shares in the company, valued at approximately $14,805,483.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Howard W. Robin sold 42,215 shares of the firm’s stock in a transaction that occurred on Tuesday, February 19th. The stock was sold at an average price of $42.33, for a total transaction of $1,786,960.95. Following the sale, the chief executive officer now owns 350,924 shares in the company, valued at $14,854,612.92. The disclosure for this sale can be found here. Insiders have sold a total of 162,705 shares of company stock worth $6,872,756 over the last 90 days. Corporate insiders own 4.31% of the company’s stock.

Several research analysts recently weighed in on the stock. Mizuho reissued a “buy” rating and set a $81.00 price objective on shares of Nektar Therapeutics in a research note on Wednesday, January 23rd. ValuEngine lowered shares of Nektar Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, January 31st. HC Wainwright reissued a “hold” rating and set a $47.00 price objective on shares of Nektar Therapeutics in a research note on Tuesday, February 19th. BMO Capital Markets assumed coverage on shares of Nektar Therapeutics in a research note on Friday, February 22nd. They set an “outperform” rating and a $75.00 price objective on the stock. Finally, TheStreet raised shares of Nektar Therapeutics from a “d+” rating to a “c” rating in a research note on Thursday, February 28th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and nine have issued a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $69.73.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally reported by Stock Observer and is the sole property of of Stock Observer. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://www.thestockobserver.com/2019/05/16/mercer-global-advisors-inc-adv-takes-204000-position-in-nektar-therapeutics-nktr.html.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company develops NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and NKTR-214, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I to treat immuno-oncology.

Further Reading: Why is momentum important to successful trading?

Want to see what other hedge funds are holding NKTR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nektar Therapeutics (NASDAQ:NKTR).

Institutional Ownership by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.